IL17A

Across TCGA pan-cancer cohorts, IL17A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL17A data layer compared with 18 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher IL17A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL17A expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

COAD, LIHC, and ACC are the cancer types where IL17A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.157	0.871	<.001	27	view →
LIHC	OS	Median	All	0.105	0.777	<.001	9	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.671	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL17A–COAD (OS)

Open the COAD breakdown →